3-碘-5-甲氧基(1h)吲唑 | 290367-99-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 3-碘-5-甲氧基(1h)吲唑
• 英文名称: 3-iodo-5-methoxy-1H-indazole
• 英文别名: 3-iodo-5-methoxy-2H-indazole
• CAS: 290367-99-6
• 化学式: C₈H₇IN₂O
• 分子量: 274.061
• InChiKey: QLWRATLJRVZESA-UHFFFAOYSA-N

物化性质

• 熔点：
  178-179 °C(Solv: ligroine (8032-32-4))
• 沸点：
  393.1±22.0 °C(Predicted)
• 密度：
  1.941±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Iodo-5-methoxyindazole
Synonyms: 3-Iodo-5-methoxy-1H-indazole

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Iodo-5-methoxyindazole
CAS number: 290367-99-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7IN2O
Molecular weight: 274.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-碘-5-甲氧基(1h)吲唑 在 palladium diacetate 氢氧化钾 、 四丁基溴化铵 、 碳酸氢钠 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 (Z)-2-acetylamino-3-{5-methoxy-1-[2-(trimethylsilanyl)ethoxymethyl]-1H-indazol-3-yl}acrylic acid methyl ester
  参考文献：
  名称：

  3-碘吲唑与2-(乙酰氨基)丙烯酸甲酯的Heck交叉偶联反应合成新型脱氢2-氮杂色氨酸及其衍生物

  摘要：

  本文描述了 3-碘吲唑与 2-(乙酰氨基)丙烯酸甲酯的 Heck 交叉偶联反应，作为催化氢化后新脱氢 2-氮杂色氨酸和受保护氨基酸衍生物的一般途径。

  DOI：

  10.1055/s-2006-950242
• 作为产物：
  描述：

  5-甲氧基-1H-吲唑 在 碘 、 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以90%的产率得到3-碘-5-甲氧基(1h)吲唑
  参考文献：
  名称：

  未保护的3-碘吲唑与频哪醇乙烯基硼酸酯的Suzuki型交叉偶联反应：在微波辐射下吲唑的C-3乙烯基化。

  摘要：

  本文中，我们报告了微波辐射下未保护的3-碘吲唑的便捷C-3乙烯基化。通过这种方法合成了十种C-5取代的3-乙烯基吲唑衍生物，其中九种是新颖的，从C-5取代的3-碘吲唑衍生物开始，以中等至优异的产率进行。在所有情况下，C-3乙烯基化衍生物都是唯一的分离产物。这种方法可以选择性地和直接地获得3-乙烯基化的吲唑，而无需N-保护。3-乙烯基吲唑可能是有趣的合成中间体，可以接触生物活性分子。

  DOI：

  10.3390/molecules23082051

文献信息

• Synthesis of 3-Indazolecarboxylic Esters and Amides via Pd-Catalyzed Carbonylation of 3-Iodoindazoles
  作者：Hans-Peter Buchstaller、Kai Wilkinson、Kasimir Burek、Yasmin Nisar

  DOI：10.1055/s-0030-1260199

  日期：2011.10

  A straightforward and effective procedure for the preparation of 1H-indazole-3-carboxylic acid esters and amides was developed. A series of functionalized 3-iodoindazoles were subjected to Pd-catalyzed carbonylations in the presence of methanol or amines, yielding the title compounds in moderate to good yield. For the majority of examples, the reaction proceeded cleanly under mild conditions, which

  开发了一种简单有效的制备1 H-吲哚-3-羧酸酯和酰胺的方法。在甲醇或胺的存在下，对一系列官能化的3-碘吲唑进行Pd催化的羰基化反应，以中等至良好的收率得到标题化合物。对于大多数实例，反应在温和条件下干净地进行，该条件易于被允许进一步合成转化的多种官能团所耐受。 羰基化-酯-酰胺-烷氧基羰基化-氨基羰基化-碘吲唑-钯催化
• ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in <i>Candida albicans</i>
  作者：Willmen Youngsaye、Cathy L Hartland、Barbara J Morgan、Amal Ting、Partha P Nag、Benjamin Vincent、Carrie A Mosher、Joshua A Bittker、Sivaraman Dandapani、Michelle Palmer、Luke Whitesell、Susan Lindquist、Stuart L Schreiber、Benito Munoz

  DOI：10.3762/bjoc.9.171

  日期：——

  The National Institutes of Health Molecular Libraries and Probe Production Centers Network (NIH-MLPCN) screened >300,000 compounds to evaluate their ability to restore fluconazole susceptibility in resistant Candida albicans isolates. Additional counter screens were incorporated to remove substances inherently toxic to either mammalian or fungal cells. A substituted indazole possessing the desired bioactivity profile was selected for further development, and initial investigation of structure–activity relationships led to the discovery of ML212.

  国家卫生研究院分子图书馆和探针生产中心网络（NIH-MLPCN）筛选了超过300,000种化合物，以评估它们恢复对耐药念珠菌的氟康唑敏感性的能力。还加入了额外的对照筛选，以去除对哺乳动物或真菌细胞有毒的物质。选择了具有所需生物活性特征的取代吲唑化合物进行进一步开发，并初步研究结构-活性关系导致了ML212的发现。
• Benzimidazoles
  申请人：Edwards L. Michael

  公开号：US20060014756A1

  公开（公告）日：2006-01-19

  The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

  本发明涉及一般式（Ix）的生理活性化合物及含有这种化合物的组合物，以及它们的前药、药学上可接受的盐和溶剂化物，还涉及在式（Ix）范围内的新化合物和它们的制备方法。这种化合物和组合物具有有价值的药物性质，特别是抑制激酶的能力。
• Pyrrolopyrazine kinase inhibitors
  申请人：Chen Shaoqing

  公开号：US08658646B2

  公开（公告）日：2014-02-25

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式I中新型吡咯吡嗪衍生物，其中变量如本文所述，其抑制JAK和SYK并且用于治疗自身免疫和炎症性疾病。
• PYRROLOPYRAZINE KINASE INHIBITORS
  申请人：Chen Shaoqing

  公开号：US20130059834A1

  公开（公告）日：2013-03-07

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用新型吡咯吡嗪衍生物（式I）的使用，其中变量如此处所述，其抑制JAK和SYK并且适用于治疗自身免疫和炎症性疾病。